JPS57163318A - Preparation of antigen - Google Patents
Preparation of antigenInfo
- Publication number
- JPS57163318A JPS57163318A JP56047841A JP4784181A JPS57163318A JP S57163318 A JPS57163318 A JP S57163318A JP 56047841 A JP56047841 A JP 56047841A JP 4784181 A JP4784181 A JP 4784181A JP S57163318 A JPS57163318 A JP S57163318A
- Authority
- JP
- Japan
- Prior art keywords
- haptene
- peptide
- carrier
- group
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
PURPOSE: To obtain a human β-interferon antigen, by converting the N-terminated peptide into haptene, and reacting the resultant haptene with a carrier in the presence of a haptene-carrier linking reagent.
CONSTITUTION: The N-terminated peptide of a human interferon expressed by formulaI(R is H, H-Phe-, -H-Leu-Gly-Phe, etc.) is converted into a haptene, which is then reacted with a carrier in an amount of 2W6 times that of the haptene and a haptene-carrier linking reagent in a molar amount of 5W10 times that of the haptene in a buffer solution at pH of 7W10, e.g. 0.2N sodium hydroxide -0.2M boric acid-0.2M potassium chloride buffer solution, at 0W40°C to give a human β-interferon antigen consisting of the peptide -carrier complex. The peptide in which R is H is obtained by reacting a peptide expressed by formula II (A is protecting group of amino group; B is OH or active group of carboxyl group) with a peptide expressed by formula II (C is protecting group of guanidino group in arginine) in a solvent, e.g. DMF.
COPYRIGHT: (C)1982,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56047841A JPS57163318A (en) | 1981-03-31 | 1981-03-31 | Preparation of antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56047841A JPS57163318A (en) | 1981-03-31 | 1981-03-31 | Preparation of antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS57163318A true JPS57163318A (en) | 1982-10-07 |
Family
ID=12786587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56047841A Pending JPS57163318A (en) | 1981-03-31 | 1981-03-31 | Preparation of antigen |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57163318A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57122054A (en) * | 1980-10-30 | 1982-07-29 | Thomae Gmbh Dr K | Tridecapeptide and manufacture |
-
1981
- 1981-03-31 JP JP56047841A patent/JPS57163318A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57122054A (en) * | 1980-10-30 | 1982-07-29 | Thomae Gmbh Dr K | Tridecapeptide and manufacture |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5377015A (en) | Preparation of fluorine-containing phosphoric acid ester | |
ES8603805A1 (en) | Process for the preparation of formic acid. | |
FR2346317A1 (en) | RECOVERY OF GLYCIN AND IMINODIACETIC ACID | |
JPS57163318A (en) | Preparation of antigen | |
EP0123951A3 (en) | Intermediates for thymosin alpha 1 | |
JPS5738750A (en) | 2,3-bis 3,4-dicarboxybenzoyloxy propyl methacrylate and its preparation | |
ES515167A0 (en) | "A PROCEDURE OF CONVERSION OF ACETOXIHEXENOIC ACIDS IN SORBIC ACID". | |
JPS57140750A (en) | Manufacture of compound having carboxylic acid amide groups | |
ES8606269A1 (en) | N-(b-mercapto-iso-butyryl)proline, derivatives and a process for their preparation | |
JPS53143388A (en) | Ultrasonic wave reception of electromagnetic type | |
EP0216696A3 (en) | Process for preparing cotarnine | |
JPS56138151A (en) | Preparation of beta-chloroalanine | |
GB2020383B (en) | Coupling for connection to a gas bottle | |
JPS5549396A (en) | Preparation of 17alpha-methylsteroid | |
JPS57163351A (en) | N-terminal peptide of beta-type interferon | |
JPS56128770A (en) | N-amino-5-fluorouracil and its preparation | |
JPS5344572A (en) | 5-alkoxy-picolic acid, its preparation and hypotensives containing the same | |
JPS5231094A (en) | Preparation of cephalexin | |
JPS5547119A (en) | Treatment of exhaust gas containing fluorine | |
JPS5410571A (en) | Washer | |
JPS53147030A (en) | Preparation of trialkyl halogenosilane | |
ES2000879A6 (en) | Inorganic acid salt of N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanylchloride and process for preparing the same. | |
JPS5439072A (en) | Peptides | |
JPS53127406A (en) | Preparation of glycols | |
JPS52136155A (en) | Preparation of adamantylamidines |